UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serum microRNA profile of rhesus macaques following ionizing radiation exposure and treatment with a medical countermeasure, Ex-Rad

Scientific reports, 2024-02, Vol.14 (1), p.4518-4518, Article 4518

2024

Volltextzugriff (PDF)

Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure

Scientific reports, 2021-06, Vol.11 (1), p.11449-11449, Article 11449

2021

Volltextzugriff (PDF)

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5504-5510

2008

Volltextzugriff (PDF)

Radioprotective Effects of ON 01210.Na upon Oral Administration

JOURNAL OF RADIATION RESEARCH, 2012, Vol.53 (3), p.368-376

2012

Volltextzugriff (PDF)

Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response

Radiation oncology (London, England), 2012-01, Vol.7 (1), p.6-6, Article 6

2012

Volltextzugriff (PDF)

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

Hematological oncology, 2015-06, Vol.33 (2), p.57-66

2015

Volltextzugriff (PDF)

Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice

Journal of radiation research, 2012-07, Vol.53 (4), p.526-536

2012

Volltextzugriff (PDF)

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent

Cancer chemotherapy and pharmacology, 2009-12, Vol.65 (1), p.177-186

2009

Volltextzugriff (PDF)

Abstract 4906: Effect of gender on the rodent pharmacokinetics of ON 123300, a dual inhibitor of ARK5 and CDK4/6, for the treatment of cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4906-4906

2018

Volltextzugriff (PDF)

Analysis of the Proteomic Profile in Serum of Irradiated Nonhuman Primates Treated with Ex-Rad, a Radiation Medical Countermeasure

Journal of proteome research, 2023-04, Vol.22 (4), p.1116-1126

2023

Volltextzugriff (PDF)

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Blood, 2018-11, Vol.132 (Supplement 1), p.3106-3106

2018

Volltextzugriff (PDF)

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

Blood, 2018-11, Vol.132 (Supplement 1), p.4379-4379

2018

Volltextzugriff (PDF)

Abstract 2172: ON 123300, an orally administered novel CDK4/6 + ARK5 inhibitor, exhibits potent antitumor activity in vivo: comparative studies with Palbociclib

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2172-2172

2017

Volltextzugriff (PDF)

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

Leukemia research, 2020-07, Vol.94, p.106369-106369, Article 106369

2020

Volltextzugriff (PDF)

Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats

European journal of drug metabolism and pharmacokinetics, 2019-08, Vol.44 (4), p.531-538

2019

Volltextzugriff (PDF)

Determination of Degradation Kinetics and Effect of Anion Exchange Resin on Dissolution of Novel Anticancer Drug Rigosertib in Acidic Conditions

AAPS PharmSciTech, 2018, Vol.19 (1), p.93-100

2018

Volltextzugriff (PDF)

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

British journal of haematology, 2013-08, Vol.162 (4), p.517-524

2013

Volltextzugriff (PDF)

Abstract LB-A21: Single-agent activity and favorable pharmaceutical properties of orally bioavailable next-generation CDK4/6 inhibitor, ON 123300

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.LB-A21-LB-A21

2015

Volltextzugriff (PDF)

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Clinical cancer research, 2014-03, Vol.20 (6), p.1656-1665

2014

Volltextzugriff (PDF)

Abstract 4687: Rigosertib synergistically enhances the anticancer activity of Cisplatin in various preclinical models of upper gastrointestinal cancers

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4687-4687

2016

Volltextzugriff (PDF)

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Clinical cancer research, 2012-04, Vol.18 (7), p.2048-2055

2012

Volltextzugriff (PDF)

Abstract 1649: Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1649-1649

2015

Volltextzugriff (PDF)

Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure

Journal of pharmacy and pharmacology, 2013-07, Vol.65 (7), p.960-969

2013

Volltextzugriff (PDF)

pH-Dependent solubility and dissolution of bupivacaine and its relevance to the formulation of a controlled release system

Journal of controlled release, 1993-03, Vol.23 (3), p.261-270

1993

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(69)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Serum microRNA profile of rhesus macaques following ionizing radiation exposure and treatment with a medical countermeasure, Ex-Rad

Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

Radioprotective Effects of ON 01210.Na upon Oral Administration

Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent

Abstract 4906: Effect of gender on the rodent pharmacokinetics of ON 123300, a dual inhibitor of ARK5 and CDK4/6, for the treatment of cancer

Analysis of the Proteomic Profile in Serum of Irradiated Nonhuman Primates Treated with Ex-Rad, a Radiation Medical Countermeasure

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials

Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine

Abstract 2172: ON 123300, an orally administered novel CDK4/6 + ARK5 inhibitor, exhibits potent antitumor activity in vivo: comparative studies with Palbociclib

Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study

Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats

Determination of Degradation Kinetics and Effect of Anion Exchange Resin on Dissolution of Novel Anticancer Drug Rigosertib in Acidic Conditions

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

Abstract LB-A21: Single-agent activity and favorable pharmaceutical properties of orally bioavailable next-generation CDK4/6 inhibitor, ON 123300

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Abstract 4687: Rigosertib synergistically enhances the anticancer activity of Cisplatin in various preclinical models of upper gastrointestinal cancers

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Abstract 1649: Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent

Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure

pH-Dependent solubility and dissolution of bupivacaine and its relevance to the formulation of a controlled release system

Suchergebnisse filtern